Department of Oncology, University of Oxford, Oxford, UK.
Br J Cancer. 2022 Mar;126(5):691-692. doi: 10.1038/s41416-021-01682-6. Epub 2022 Jan 11.
Cancer patients with COVID-19 have reduced survival. While most cancer patients, like the general population, have an almost 100% rate of seroconversion after COVID-19 infection or vaccination, patients with haematological malignancies have lower seroconversion rates and are far less likely to gain adequate protection. This raises the concern that patients with haematological malignancies, especially those receiving immunosuppressive therapies, may still develop the fatal disease when infected with COVID-19 after vaccination. There is an urgent need to develop Guidelines to help direct vaccination schedules and protective measures in oncology patients, differentiating those with haematological malignancies and those in an immunocompromised state.
癌症患者感染 COVID-19 后生存率降低。虽然大多数癌症患者与普通人群一样，在 COVID-19 感染或接种疫苗后几乎 100%的血清转化率，但血液恶性肿瘤患者的血清转化率较低，获得充分保护的可能性也小得多。这让人担心，接种疫苗后感染 COVID-19 时，血液恶性肿瘤患者，尤其是接受免疫抑制治疗的患者，仍可能患上致命疾病。迫切需要制定指南，帮助指导肿瘤患者的疫苗接种计划和保护措施，区分血液恶性肿瘤患者和免疫功能低下患者。
